Neoadjuvant Nivolumab/Relatlimab Induces High Rates of Pathologic Responses in Patients with Locally Advanced MMR-deficient Colon Cancer
Findings from the NICHE-3 study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1548 results
Neoadjuvant ICI Without Chemotherapy Demonstrates Potential Efficacy in Patients with Early-Stage TNBC
Findings from the BELLINI study
FDA Approves Inavolisib with Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-mutated, HR-positive, HER2-negative Advanced Breast Cancer
Evidence for efficacy is based on the results from the INAVO120 study
EMA Recommends Extension of Indications for Tislelizumab to First-Line Treatment of Gastric or GEJ Adenocarcinoma and Oesophageal Squamous Cell Carcinoma
New indications concern patients with previously untreated gastric or gastro-oesophageal junction adenocarcinoma and oesophageal squamous cell carcinoma
Perioperative Durvalumab Plus Neoadjuvant Chemotherapy Improves EFS and OS in Cisplatin-Eligible Patients with Muscle Invasive Bladder Cancer
Findings from the NIAGARA study
Adding Cadonilimab to First-Line Standard Chemotherapy Significantly Improves PFS and OS in Patients with Persistent, Recurrent, or Metastatic Cervical Cancer
Findings from the COMPASSION-16 study
iDFS Benefit with Ribociclib Plus Nonsteroidal Aromatase Inhibitor in Patients with HR-positive, HER2-negative Early Breast Cancer
Final invasive disease-free survival results from the NATALEE study
FDA Approves Zolbetuximab-clzb with Chemotherapy for Gastric or Gastro-Oesophageal Junction Adenocarcinoma
FDA also approved the VENTANA CLDN18 (43-14A) RxDx Assay as a companion diagnostic device
EMA Recommends Granting a Marketing Authorisation for Catumaxomab
It is intended for the intraperitoneal treatment of malignant ascites
Greater OS Benefit Among Patients with Advanced Cancer Treated with Matched Targeted Therapy Based on Biomarkers Identified by ctDNA Genotyping
Findings from the SCRUM-Japan GOZILA study
Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab Prolongs OS Among Patients with Early-Stage TNBC
Findings from the KEYNOTE-522 study
Five Fraction SBRT Noninferior to Moderately Fractionated Image-Guided Radiotherapy for Patients with Low to Intermediate Risk Localised Prostate Cancer
Findings from the PACE-B study